ArticleJCI insight2022
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.
Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 45 citations in OpenAlex.
- Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.JCI insight · 2022Trial
- Newborn IgG and IgM antibodies to maternal SARS-CoV-2 infection in pregnancy and child neurodevelopmental outcomes.Brain, behavior, and immunity · 2026Article
- Preexisting Humoral Immunity Against Seasonal Coronaviruses Enhances Antibody Responses on SARS-CoV-2 Vaccination.Open forum infectious diseases · 2026Article
- Seroprevalence of endemic and emergent coronaviruses among SARS-COV-2 patients and healthcare workers in Abidjan, Côte d'Ivoire.BMC infectious diseases · 2026Article
- Cross-Reactive IgG Antibody Responses to SARS-CoV-2 in Older Adults Following Seasonal Coronavirus Infection in Jiangsu, China (2015-2017).Influenza and other respiratory viruses · 2026Article
- Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms.The Journal of experimental medicine · 2026Article
- Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses.Communications biology · 2026Article
- Article
- Post-transfusion activation of coagulation pathways during severe COVID-19 correlates with COVID-19 convalescent plasma antibody profiles.The Journal of clinical investigation · 2025Article
- HCoV-NL63 and HCoV-HKU1 seroprevalence and its relationship with the clinical features of COVID-19 patients from Villavicencio, ColombiaBiomedica : revista del Instituto Nacional de Salud · 2024Article
- Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls.The Journal of infectious diseases · 2024Article
- Article
- Darwin review: the evolution of virulence in human pathogens.Proceedings. Biological sciences · 2024Review
- EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation.Frontiers in immunology · 2024Article
- Immune imprinting and next-generation coronavirus vaccines.Nature microbiology · 2023Review
- Selection for immune evasion in SARS-CoV-2 revealed by high-resolution epitope mapping and sequence analysis.iScience · 2023Article
- Differential abundance of IgG antibodies against the spike protein of SARS-CoV-2 and seasonal coronaviruses in patients with fatal COVID-19.Virology journal · 2023Article
- The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.Nature reviews. Immunology · 2023Review
- Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review.Biology · 2023Review
- First Impressions Matter: Immune Imprinting and Antibody Cross-Reactivity in Influenza and SARS-CoV-2.Pathogens (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors at 20 institutions in 6 countries.
Funding
Abstract
The role of immune responses to previously seen endemic coronavirus epitopes in severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and disease progression has not yet been determined. Here, we show that a key characteristic of fatal outcomes with coronavirus disease 2019 (COVID-19) is that the immune response to the SARS-CoV-2 spike protein is enriched for antibodies directed against epitopes shared with endemic beta-coronaviruses and has a lower proportion of antibodies targeting the more protective variable regions of the spike. The magnitude of antibody responses to the SARS-CoV-2 full-length spike protein, its domains and subunits, and the SARS-CoV-2 nucleocapsid also correlated strongly with responses to the endemic beta-coronavirus spike proteins in individuals admitted to an intensive care unit (ICU) with fatal COVID-19 outcomes, but not in individuals with nonfatal outcomes. This correlation was found to be due to the antibody response directed at the S2 subunit of the SARS-CoV-2 spike protein, which has the highest degree of conservation between the beta-coronavirus spike proteins. Intriguingly, antibody responses to the less cross-reactive SARS-CoV-2 nucleocapsid were not significantly different in individuals who were admitted to an ICU with fatal and nonfatal outcomes, suggesting an antibody profile in individuals with fatal outcomes consistent with an "original antigenic sin" type response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.